Hikma bids £80m for Jordanian drug maker
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Hikma Pharmaceuticals has offered $163.6m (£80m) to buy Arab Pharmaceutical Manufacturing, a Jordanian maker of branded generic drugs, it said yesterday.
Hikma is also based in Jordan and has been listed on the London Stock Exchange since 2005. It develops and markets generic and brand-name drugs including folic acid, lithium and a treatment for hypertension. It sells them in the Middle East, North Africa, Europe and the US.
If the acquisition is completed, Hikma would gain 85 products registered in 22 countries and a sales and marketing team of 200 operating in 14 Middle East and North African markets.
The offer is subject to due diligence and the approval of regulators and the target shareholders.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments